StockData
GSK plc logo

GSK plc (GSK) stock

GSKNYSEPharmaceutical PreparationsAlso trades as GLAXF
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$48.58−0.66 (-1.34%)

Close on Nov 18, 2026Market cap $104.82BP/E 13.2Yield –

GSK operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was £7.93B, up 97.3% from the year before. Over ten years it grew -2.6% a year on average. The highest annual figure on record is £10.32B in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025£7.93B+97.3%
FY2024Dec 31, 2024£4.02B-40.4%
FY2023Dec 31, 2023£6.75B+4.8%
FY2022Dec 31, 2022£6.43B+47.6%
FY2021Dec 31, 2021£4.36B-27.1%
FY2020Dec 31, 2020£5.98B-14.1%
FY2019Dec 31, 2019£6.96B+27.0%
FY2018Dec 31, 2018£5.48B+34.2%
FY2017Dec 31, 2017£4.09B+57.3%
FY2016Dec 31, 2016£2.60B-74.8%
FY2015Dec 31, 2015£10.32B–

More GSK figures

See a number that looks wrong?